Interviews

Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.

Roby Thomas, MD discusses chemotherapy shortages and the impact these shortages have had on oncology research.

Ashwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.

In an interview, Rohan Garje, MD, discussed his research on comparing the outcomes of sarcomatoid and classic urothelial carcinoma of bladder.

In an interview with Targeted Oncology™, Q2 2023 Oncology Icons honoree, Thaddeus Beck, MD, FACP, discussed his 30 plus years of experience in clinical practice.

In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the initial results of the addition of acalabrutinib to bendamustine and rituximab to treat patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Hope S. Rugo, MD, explained the results of the phase 3 CAPItello-291 trial, and the potential impact of the study on the breast cancer treatment paradigm.

Frederick Locke, MD, discuss 2 allogeneic CD19-directed chimeric antigen receptor T-cell agents for the treatment of relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

Tara Seery, MD, explains the next steps for the QUILT 88 study looking at a novel combination of therapies for patients with metastatic pancreatic cancer.

Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.

Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.

Jeffrey Dome, MD, PhD, discusses how the use of atezolizumab has impacted the treatment of pediatric patients with alveolar soft part sarcoma.

Jonathan C. Trent, MD, PhD, discusses the molecular analyses of the INTRIGUE study, which was supported by Caris Life Science’s Precision Oncology Alliance, investigating patients with GIST that were presented at ASCO 2023.

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

In an interview with Targeted Oncology, BJ Rimel, MD, discussed the rationale, methods, and design of this phase 2 study for patients with endometrial cancer.

Nicholas J. Roberts, discusses real-world research around the adoption of germline testing for breast cancer, and the testing gap in certain racial groups.

In an interview with Targeted Oncology, Yann-Alexandre Vano, MD, discussed the implications of the findings from the phase 2 BIONIKK trial of second-line treatment for patients with metastatic RCC.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

In an interview with Targeted Oncology, Benjamin L. Schlechter, MD, discussed the potential benefit of TAC T cells for patients with solid tumors.

Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.

In an interview with Targeted Oncology, Nicholas Girard, MD, PhD reviews 3 key abstracts presented at the ELCC 2023, in which different targeted therapies were administered to patients with EGFR-mutant non–small cell lung cancer in clinical trial and real-world settings.

In an interview, Harry Erba, MD, PhD, compared ziftomenib with other Menin inhibitors and discussed data from the phase 1/2 trial evaluating the menin-KMT2A inhibitor in patients with AML.

In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.